Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
cvjDUy3VQNpSS5JB